Global next generation sequencing (NGS) market is expected to reach USD 16.6 billion by the year 2025, according to the latest research available at Market Study Report, report provides extensively data on market share, growth, trends and forecasts for the period 2017-2025.
 

A complete human genome can be sequenced in just one day by means of next generation sequencing. By offering high throughput, speed, flexibility, and decreased sequencing cost, the launch of NGS technologies has brought considerable transformation in sequencing technologies. In terms of single sequencing, the NGS has the ability to create nucleotide sequence data. The wide range of applications where NGS is used include genetic disease research, cancer research, personalized medicines, biological drug discovery, agriculture research, and newborn sequencing metagenomics, etc.
 

According to the report, next generation sequencing is in high demand for the investigation of cancer, inherited genetic diseases, HLA typing, and detection of infectious diseases, as it scans targeted genome in very less time, thereby propelling industry growth over the predicted timeline.
 

The report bifurcates the global market for next generation sequencing on the basis of region, user, products, technology, and application. Based on application, the global NGS market is categorized into genetic screening, drug discovery or personalized medicine, diagnostics or infectious diseases, agricultural and animal research, as well as others. As per the report, the drug discovery/personalized medicine segment is predicted to account for a huge share of the global next generation sequencing market with respect to the application landscape in the year 2017. The growing demand for NGS base test for cancer and infectious diseases, and increasing focus on building and offering NGS-based diagnostic tests has significantly contributed towards the high market share of the fragment in the global market. Furthermore, the swelling R&D activities across the globe are adding impetus to the growth of the market.
 

Speaking of technological distribution, the NGS market is sectioned into Methyl Sequencing, De Novo Sequencing, Chip Sequencing, RNA Sequencing, Whole Exome Sequencing, Targeted Re-Sequencing, and Whole Genome Sequencing. In terms of technology, re-sequencing and targeted sequencing amassed a huge share of the global market. The targeted sequencing decreases process cost, it has a prespecified target, and needs smaller datasets. Furthermore, the burgeoning demand for target specific genomic studies is anticipated to drive segmental growth during the forecast period.
 

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/1700726/
 

In terms of product, the market is divided into reagents and consumables, services, and instruments. Based on consumables the global market is further classified into sample preparation consumables, as well as other consumables. The sample preparation market encompasses library preparation, quality control consumables, end repair, DNA fragmentation, size selection, and A-tailing, etc. In terms of services, the global market is bifurcated into sequencing services and data management services. The sequencing service market encompasses RNA Sequencing Chip-Seq, targeted Re-Sequencing, De Novo Sequencing, Methyl-Seq, etc., whereas data management services encompass NGS data analysis services, NGS data analysis software and workbenches, management, and NGS storage.
 

With respect to the end user landscape, the global market is further bifurcated into pharmaceutical and biotechnology companies, healthcare institutions, research & academic centers, and others. According to the report, the research and academics end user segment amassed the biggest share of the overall market. The astounding performance of this segment can be attributed to the increasing application of next generation sequencing tools for research initiatives. The report also cites that the hospitals & clinics market segment is anticipated to record a high CAGR during the estimated timeframe on account of burgeoning collaboration between hospitals, biotech, and pharmaceutical firms to build advanced test kits for diagnosis of illnesses.
 

The leading players profiled in the global next generation sequencing market include Eurofins Scientific, Macrogen, Inc., Agilent Technologies, Inc., Perkin Elmer, Inc., GATC Biotech AG, Pacific Biosciences of California, Inc., Oxford Nanopore Technologies, Ltd., BGI (Beijing Genomics Institute), QIAGEN N. V., Roche Holding AG, Illumina, Inc., and Thermo Fisher Scientific Inc. among others.